Hypothalamo–Pituitary Axis

1. Big Picture (Orientation Logic)

• The pituitary gland (hypophysis) is the master endocrine relay between the brain (hypothalamus) and the peripheral endocrine organs.
• It sits at the base of the brain, physically connected to the hypothalamus and functionally controlled by it.
• Its design reflects dual control:
• Neural control → posterior pituitary
• Endocrine (portal blood) control → anterior pituitary

2. Size, Weight & Sexual Dimorphism

• Weight: ~0.5 g in adults
• Size: 10–15 mm in each dimension
• Sex difference:
• Heavier in women
• Enlarges during pregnancy

➡️ Logic: reflects increased hormonal demand (especially prolactin).

3. Exact Location & Relations (Exam-Critical Spatial Logic)

Position

• Protrudes from the inferior surface of the hypothalamus
• Lies in sella turcica of the sphenoid bone
• Covered by diaphragma sellae (dural fold)

Key Neighbours

• Superior → optic chiasm
• Lateral → cavernous sinuses
• Superior/posterior → floor of the third ventricle

➡️ Logic:

• Optic chiasm proximity → visual field defects in pituitary tumours
• Cavernous sinus proximity → cranial nerve palsies

4. Structural Division (Why Two Lobes Exist)

The pituitary is not one organ embryologically or functionally.

A. Anterior Pituitary (Adenohypophysis)

• Glandular
• Hormone synthesis occurs here
• Subdivisions:
• Pars distalis → main hormone-secreting part
• Pars tuberalis → wraps around stalk

B. Posterior Pituitary (Neurohypophysis)

• Neural tissue
• Stores and releases hypothalamic hormones
• Components:
• Pars nervosa
• Pituitary stalk (infundibulum)
• Median eminence

➡️ Logic:

Anterior = makes hormones

Posterior = releases hormones made in hypothalamus

5. Pituitary Stalk & Hypothalamus (Connection Logic)

Hypothalamic Boundaries

• Anterior → optic chiasm
• Posterior → mammillary bodies
• Lateral → temporal lobes (sulci)
• Dorsal → thalamus (hypothalamic sulcus)

Median Eminence

• Central inferior hypothalamic region
• Highly vascular
• Contains primary capillary plexus of portal system

Connections

• Neural connections → posterior pituitary
• Endocrine (portal) connections → anterior pituitary

➡️ Logic: one stalk, two communication methods.

6. Blood Supply (High-Yield Logic Flow)

Arterial Supply

• Hypothalamus → Circle of Willis
• Anterior pituitary → Superior hypophyseal arteries
• Posterior pituitary → Inferior hypophyseal arteries

Portal System Logic (Why It Exists)

1. Superior hypophyseal arteries
2. → Primary capillary plexus in median eminence
3. → Long portal veins (run along ventral stalk)
4. → Secondary capillary plexus in anterior pituitary
5. → Hormones released locally

➡️ Purpose: undiluted, rapid hypothalamic control

• Short portal veins from inferior hypophyseal system → minor contribution
• Anterior pituitary = one of the most vascular tissues in mammals

Venous Drainage

• Anterior pituitary → cavernous sinus→ superior & inferior petrosal sinuses→ jugular vein

7. Histology — Hypothalamic Neurons (3 Types)

1. Magnocellular Neurons

• Secrete:
• AVP (vasopressin)
• Oxytocin
• Cell bodies:
• Supraoptic nucleus
• Paraventricular nucleus
• Axons descend via stalk → posterior pituitary → hormone released into blood

2. Hypophysiotrophic Neurons

• Location:
• Paraventricular nucleus
• Arcuate nucleus
• Medial basal hypothalamus
• Release hormones into portal circulation
• Hormones:
• TRH
• CRH
• GHRH
• Somatostatin
• GnRH
• Dopamine

➡️ Logic: control anterior pituitary secretion.

3. Projection Neurons

• Found in:
• Paraventricular nucleus
• Arcuate nucleus
• Lateral hypothalamic area
• Project to:
• Brainstem
• Spinal cord
• Regulate autonomic nervous system

8. Pituitary Histology

Adenohypophysis

• Cell types (based on staining):
• Basophils
• Acidophils
• Chromophobes
• Staining reflects hormone-containing granules

Neurohypophysis

• Not glandular
• Composed of:
• Axon bundles from hypothalamic neurons
• Supporting glial cells

9. Embryology (Why Tumours Occur Where They Do)

Anterior Pituitary

• Origin: oral ectoderm
• Forms from Rathke pouch
• Appears at weeks 4–5
• Pouch:
• Detaches from oral cavity
• Lumen → small cleft
• Upper part → pars tuberalis
• Remnants → craniopharyngiomas

Posterior Pituitary

• Origin: neural tissue
• Downward evagination from floor of 3rd ventricle
• Lumen closes → neural stalk
• Upper recess → median eminence

Key Developmental Milestones

• Cleft of Rathke pouch → boundary between lobes
• Hypothalamo–pituitary axis established by week 20
• Hormone-secreting cell differentiation → transcription factor-driven

10. Physiology — Hypothalamic Functions (Focused Scope)

General roles:

• Autonomic nervous system control
• Thermoregulation
• Hunger & thirst
• Memory, behaviour, emotions

Endocrine focus:

• Regulates pituitary hormone secretion via:
• Neural pathways
• Portal circulation

Final Logic Lock (One-Line Integration)

The pituitary gland is a dual-origin, dual-control endocrine organ lying in the sella turcica, structurally and embryologically divided into glandular anterior and neural posterior lobes, connected to the hypothalamus by neural axons and a specialized portal circulation that allows precise central regulation of endocrine function.

Anterior Pituitary Gland — Logic-Based Physiology Note

1. Core Regulatory Logic (How the Anterior Pituitary Is Controlled)

The anterior pituitary is regulated by three interacting control systems:

1. Hypothalamic input
• Releasing factors
• Inhibitory factors
• Delivered via the hypothalamo–hypophysial portal system
2. Feedback from circulating peripheral hormones
• Mainly negative feedback
• Acts at:
• Pituitary level
• Hypothalamic level
3. Local pituitary control
• Paracrine secretion
• Autocrine secretion

➡️ Logic: control is central + peripheral + local, allowing tight hormonal precision.

2. Major Hormones of the Anterior Pituitary (Clinical Set)

The anterior pituitary synthesises and secretes six major hormones:

1. Growth hormone (GH / somatotrophin)
2. Thyroid-stimulating hormone (TSH / thyrotrophin)
3. Adrenocorticotrophin (ACTH)
4. Follicle-stimulating hormone (FSH)
5. Luteinising hormone (LH)
6. Prolactin (PRL)

➡️ Note: physiological control of TSH and ACTH described elsewhere (not repeated here).

3. Growth Hormone (GH)

Cell of Origin

• Secreted by somatotrophs
• Somatotrophs = 40–50% of anterior pituitary cells

Structure

• Single-chain polypeptide
• 191 amino acids
• Structural homology with:
• Prolactin
• Human chorionic gonadotrophin (hCG)
• hCG = GH variant synthesised exclusively in placenta

Physiological Actions of GH

A. Growth & Differentiation

• Promotes:
• Linear growth
• Cell differentiation
• Tissue growth
• Important in lactation(Lactation is highly energy-demanding. GH ensures the mother can meet this demand)

B. Protein Metabolism

• ↑ Amino acid uptake
• ↑ Protein synthesis
• ↓ Protein oxidation

➡️ Net effect: anabolic

C. Fat Metabolism

• Stimulates:
• Triglyceride breakdown
• Fatty acid oxidation in adipocytes

➡️ Net effect: lipolysis

D. Carbohydrate Metabolism

• Maintains blood glucose levels by:
• ↓ Insulin-mediated glucose uptake in peripheral tissues
• ↓ Insulin-mediated glucose synthesis in liver
• Stimulates insulin secretion
• GH administration → hyperinsulinaemia

➡️ Logic: GH is diabetogenic but insulin-stimulating

4. IGF System (Indirect GH Effects)

GH acts:

• Directly
• Indirectly via insulin-like growth factors (IGFs)

IGF Family

• Insulin
• IGF-I
• IGF-II

All share:

• Structural similarities
• Metabolic roles
• Roles in cellular proliferation & differentiated tissue function

(via IGF-I receptor)

Developmental Roles

• IGF-II → major fetal growth factor
• IGF-I → key postnatal growth mediator
• Insulin → contributes to fetal growth
• Explains fetal macrosomia in maternal diabetes

5. Regulation of GH Secretion

Hypothalamic Control

• GHRH → stimulates GH
• Somatostatin → inhibits GH

GHRH

• Released from median eminence
• Travels via portal capillaries to anterior pituitary

Somatostatin

• 14-amino-acid peptide
• Synthesised mainly in anterior periventricular nuclei

Physiological Modulators of growth hormone

• Sleep, decreased at REM sleep
• Exercise
• Stress
• Blood glucose levels

Feedback Control

• IGF-I:
• Negative feedback on:
• Pituitary
• Hypothalamus
• Estradiol:
• Increases tissue sensitivity to GH

6. GH Secretion Pattern

• Begins early fetal life
• Continues throughout life
• Secretion progressively declines with age
• Pulsatile secretion

Age-Related Pattern

• High in childhood
• Peak at puberty
• Falls in adulthood

Adult Pattern

• ~5 pulses per 24 hours
• Largest pulse:
• At onset of sleep
• Half-life: ~20 minutes

7. Prolactin (PRL)

Cell of Origin

• Secreted by lactotrophs
• Lactotrophs = 10–15% of anterior pituitary cells

Structure

• Single-chain protein
• 199 amino acids
• Three disulphide bridges
• Strong structural homology with GH
• PRL and GH receptors are also structurally similar

Estrogen Effects

• Estrogen:
• Stimulates lactotroph proliferation
• Result:
• Increased lactotroph numbers in premenopausal women
• Marked increase during pregnancy

Physiological Actions

Primary Role in Humans

• Preparation of female breast for lactation

Other Sites of Action

• Gonads
• Lymphoid cells
• Liver

➡️ PRL receptors widely expressed; many functions remain unclear.

Key Clinical Observations

• Men have same PRL levels as non-lactating women
• PRL affects:
• Hypothalamo–pituitary–gonadal axis
• Inhibits pulsatile GnRH secretion
• Alters steroidogenic enzyme activity

Regulation of PRL Secretion

Unique Hypothalamic Control

• Predominantly inhibitory

(unlike all other pituitary hormones)

➡️ Damage to hypothalamus → increased PRL

Inhibitory Factors

• Dopamine (main regulator)
• Released into portal veins
• Somatostatin

Stimulatory Factors

• TRH
• Other releasing factors
• Pregnancy
• Lactation (suckling)
• Estrogen
• Opioids
• Dopamine D2 receptor antagonists
• Sleep
• Stress

Additional Control

• PRL can regulate its own secretion via a short feedback loop
• Secretion is pulsatile
• Levels increase with sleep
• need for surfactant synthesis of fetus

8. Gonadotrophins (FSH & LH)

Chemical Nature

• Glycoproteins
• Molecular weight ~30 000 Daltons
• Structure:
• Common α-subunit
• Hormone-specific β-subunit (confers biological specificity)

➡️ hCG belongs to same hormone family.

Cells of Origin

• Secreted by gonadotrophs
• Gonadotrophs = 10–15% of anterior pituitary cells

Receptors & Signalling

• Receptors:
• G-protein-coupled receptors
• Binding activates:
• Adenylate cyclase
• ↑ cAMP

Physiological Actions

Testis

• LH → Leydig cells (interstitial cells)
• FSH → Sertoli cells

Ovary

• Both hormones act on multiple cell types

➡️ Central role in steroidogenesis

Isoforms & Clinical Measurement

• Multiple circulating isoforms of LH & FSH
• Biological potency depends on:
• Degree of glycosylation
• Sites of glycosylation
• Electrical charge

➡️ Consequence:

• Assay concentration ≠ true biological activity in all cases

Final Logic Lock (Integrated One-Sentence Concept)

The anterior pituitary is a glandular endocrine organ regulated by hypothalamic releasing and inhibitory hormones, peripheral feedback, and local autocrine/paracrine signals, producing six key hormones whose secretion patterns, molecular structures, signalling pathways, and feedback controls are precisely adapted to growth, metabolism, reproduction, and lactation.

POSTERIOR PITUITARY GLAND (NEUROHYPOPHYSIS)

Hormones

• Secretes arginine vasopressin (AVP) and oxytocin (OXY).
• AVP and OXY are small peptides with strong structural homology.
• Each consists of 9 amino acids arranged in a ring structure with a short tail.

Sites of Synthesis

• AVP:
• Mainly synthesised in supraoptic nuclei.
• To a lesser extent in paraventricular nuclei.
• OXY:
• Mainly synthesised in paraventricular nuclei.
• To a lesser extent in supraoptic nuclei.

Neuronal Types

• Magnocellular neurosecretory neurons:
• Synthesise AVP and OXY.
• Hormones are transported to and released from the posterior pituitary.
• Parvocellular neurons:
• Control anterior pituitary hormone secretion.

Hormone Synthesis and Transport

• AVP and OXY are synthesised as large prohormones.
• Prohormones are packaged into secretory granules.
• Granules are transported by axonal flow to nerve terminals (Herring bodies) in the neurohypophysis.
• During transport, prohormones are cleaved into:
• Biologically active hormone (AVP or OXY).
• A larger polypeptide fragment (neurophysin).

Neurophysins

• Neurophysin II:
• Cleaved from vasopressin prohormone.
• Neurophysin I:
• Cleaved from oxytocin prohormone.(OXY_PARA-1)
• Neurophysins are co-secreted with AVP and OXY during electrical activation of neurons.

ARGININE VASOPRESSIN (AVP)

Nomenclature

• Named for its pressor effect (raises blood pressure).
• Also called antidiuretic hormone (ADH) due to renal actions.
• AVP and ADH are used interchangeably.

Receptors and General Role

• AVP has three known receptors.
• Acts with aldosterone and atrial natriuretic peptide to regulate blood volume and pressure.

Renal Actions

• Acts on V2 receptors (G-protein linked).
• Receptors located on capillary (basal) side of:
• Distal convoluted tubules
• Collecting ducts
• V2 receptor activation → ↑ cAMP.
• cAMP activates a kinase on the luminal (apical) membrane.
• Leads to insertion of aquaporin water channels into luminal membrane.
• Water moves:
• Into tubular cells
• Across basal membrane
• Into interstitium
• Back into circulation

Osmotic Gradient

• Cortex → medulla osmotic gradient created by loop of Henle counter-current mechanism.
• Collecting ducts pass through this gradient.
• Increasing amounts of solute-free water are reabsorbed.
• This process is controlled by aquaporins, and therefore by AVP.

Regulation of AVP Secretion

Osmolality

• ↑ Extracellular fluid osmolality → ↑ AVP release.
• Detected by osmoreceptors located in:
• Hypothalamus
• Circumventricular organs
• Systemic viscera
• Osmoreceptors also stimulate thirst.
• Net effect:
• ↑ Water retention
• ↓ Serum osmolality

Blood Volume and Pressure

• AVP secretion stimulated by 5–10% reduction in effective blood volume.
• Detected by stretch receptors:
• Baroreceptors
• Other cardiovascular receptors
• Example:
• Haemorrhage → ↑ AVP → ↑ water retention → ↑ blood volume
• Increased volume/pressure → ↓ AVP secretion

Other Stimuli

• Emotional stress
• Pain
• Drugs
• Nausea and vomiting (very potent)
• Important in postoperative water balance

Inhibition

• Alcohol strongly inhibits AVP release.
• As little as 30–90 ml of whiskey can cause inhibition.
• Results in:
• Water loss
• Dehydration
• Hangover symptoms

Vascular Actions

• AVP causes vasoconstriction of arteriolar smooth muscle.
• Mediated via:
• Calcium
• Phospholipase-C second-messenger pathway
• Important in maintaining blood pressure after haemorrhage.

Endocrine Interaction

• AVP potentiates CRH action on pituitary corticotrophs.

OXYTOCIN (OXY)

• Peptide hormone
• Nonapeptide → 9 amino acids
• Synthesized in hypothalamus
• Released from posterior pituitary

General Characteristics

• Neuropeptide acting as:
• Neurohormone
• Neurotransmitter
• Neuromodulator
• Produced centrally in magnocellular hypothalamic neurons.

Peripheral Production

• Also synthesised in:
• Uterus
• Placenta
• Amnion
• Corpus luteum
• Testis
• Heart

Receptor Distribution

• OXY receptors found in:
• Kidney
• Heart
• Thymus
• Pancreas
• Adipocytes

Physiological Actions

Lactation

• Major action in humans.
• Neuroendocrine reflex during suckling.
• Causes contraction of myoepithelial cells around mammary alveoli.
• Leads to milk let-down.

Parturition

• Major role in animals.
• In humans:
• Less evidence for primary role
• Induces powerful uterine contractions
• Synthetic OXY used:
• To induce labour
• To reduce postpartum haemorrhage

Renal Effects

• Can stimulate AVP V2 receptors.
• High-dose IV OXY (in 5% dextrose) can cause:
• Water retention
• Iatrogenic hyponatraemia
• No naturally occurring disease due to excess OXY.

GnRH (Gonadotropin-Releasing Hormone) from hypothalamus

Origin & Nature

• Decapeptide hormone
• Synthesized in hypothalamus
• Mainly from arcuate nucleus
• Secreted into portal hypophyseal circulation
• Acts on gonadotrophs of anterior pituitary

Secretion Pattern

• Secreted in a pulsatile manner ✅ (ESSENTIAL)
• Pulse generator located in hypothalamus
• Frequency and amplitude determine biological effect
• Continuous (non-pulsatile) GnRH →
• Down-regulation of GnRH receptors
• ↓ FSH & LH secretion

➕ Added

• Pulsatility is mandatory for normal gonadotropin secretion
• Loss of pulsatility → hypogonadotropic hypogonadism

Neuroendocrine Control (KNDY Neurons)

• Kisspeptin:
• Directly stimulates GnRH neurons
• Drives pulsatile GnRH secretion
• KNDY neurons (Kisspeptin, Neurokinin B, Dynorphin):
• Coordinate pulse generation
• Estrogen negative feedback:
• Suppresses kisspeptin release
• Some KNDY neurons provide inhibitory signals → ↓ pulse frequency

➕ Added

• Neurokinin B → stimulates GnRH pulses
• Dynorphin → inhibits GnRH pulses

Hormonal Feedback Regulation

• Estrogen:
• ↑ GnRH pulse frequency
• Progesterone:
• ↓ GnRH pulse frequency
• During luteal phase:
• Progesterone dominance → slow pulses
• End of luteal phase:
• ↓ Estrogen & progesterone → pulse frequency rises again

➕ Added

• Estrogen has dual feedback:
• Negative feedback most of cycle
• Positive feedback at mid-cycle → LH surge

Physiologic Effects of Pulse Frequency

• High-frequency pulses → ↑ LH secretion
• Low-frequency pulses → favor FSH secretion

➕ Added

• Differential gene transcription of LH β and FSH β subunits depends on pulse pattern

Ovulatory Phase Changes

• At ovulation:
• Gonadotrophs show self-priming
• ↑ sensitivity to GnRH
• Leads to LH surge

Neurotransmitter Modulation

• Pulse generator:
• Stimulated by:
• Epinephrine (EP)
• Norepinephrine (NEP)
• Inhibited by:
• Enkephalins
• β-endorphins

➕ Added

• Stress, weight loss, excessive exercise → ↑ β-endorphins → ↓ GnRH

Action at Pituitary

• GnRH binds to GnRH receptors (G-protein coupled)
• Stimulates release of:
• LH (more prominent effect)
• FSH

➕ Added

• Acts via IP₃–DAG pathway → Ca²⁺ influx
• Promotes synthesis + release of gonadotropins

Clinical Correlation (Very High Yield)

➕ Added

• GnRH agonists (continuous) → medical castration

Used in:

1. Endometriosis
2. Fibroids
3. Prostate cancer
• Pulsatile GnRH therapy:
• Treats hypothalamic amenorrhea
• Kisspeptin deficiency → delayed puberty

EXAM REFLEX BLOCK — Posterior Pituitary (Neurohypophysis) + GnRH Axis 🧠🎯

Use this as final-hour consolidation. Every line is examiner-triggered.

POSTERIOR PITUITARY (NEUROHYPOPHYSIS)

Core Identity

• Does NOT synthesise hormones → only stores & releases.
• Hormones made in hypothalamic magnocellular neurons.
• Hormones:
• AVP (ADH)
• Oxytocin
• Both are nonapeptides (9 AAs) with ring + tail, high homology.

Sites of Synthesis (Classic Pairing)

• AVP → mainly supraoptic nucleus
• Oxytocin → mainly paraventricular nucleus
• Minor cross-synthesis exists → examiners love “mainly vs partly”.

Transport & Storage

• Synthesised as large prohormones.
• Packaged in secretory granules.
• Transported by axonal flow down pituitary stalk.
• Stored in Herring bodies.
• During transport → cleaved into:
• Active hormone
• Neurophysin

Neurophysins (Very Tested)

• Neurophysin I → with oxytocin
• Neurophysin II → with vasopressin
• Co-secreted during neuronal depolarisation.
• Function: carrier + stabilisation, not hormonal action.

ARGININE VASOPRESSIN (AVP / ADH)

Names = Functions

• ADH → renal water retention
• Vasopressin → vasoconstriction

Renal Action (V2 Pathway – Gold Standard)

• Receptor: V2 (Gs-coupled).
• Location: basolateral membrane of:
• DCT
• Collecting ducts
• Mechanism:
• ↑ cAMP → protein kinase
• Inserts aquaporin-2 into luminal membrane
• Result:
• ↑ water reabsorption
• ↓ serum osmolality

👉 Key line: AVP controls water reabsorption, not sodium.

Why AVP Works (Osmotic Gradient)

• Cortico-medullary gradient created by:
• Loop of Henle counter-current system
• Collecting ducts pass through gradient.
• AVP decides how much water follows.

Regulation of AVP Secretion

1. Osmolality (Most Sensitive)

• ↑ plasma osmolality → ↑ AVP
• Detected by osmoreceptors:
• Hypothalamus
• Circumventricular organs
• Also stimulates thirst.

2. Volume / Pressure

• Requires 5–10% fall (less sensitive).
• Detected by baroreceptors.
• Example:
• Haemorrhage → ↑ AVP → water retention → BP support.

3. Other Powerful Stimuli

• Pain
• Stress
• Drugs
• Nausea & vomiting (very potent)
• Post-operative state → water retention.

Inhibition

• Alcohol → strong AVP suppression.
• Leads to:
• Diuresis
• Dehydration
• Hangover

Vascular Action

• Acts on V1 receptors.
• Uses PLC → Ca²⁺ pathway.
• Causes arteriolar vasoconstriction.
• Critical in shock / haemorrhage.

Endocrine Interaction

• AVP potentiates CRH → ↑ ACTH release.

OXYTOCIN (OXY)

Nature

• Acts as:
• Neurohormone
• Neurotransmitter
• Neuromodulator
• Produced in magnocellular neurons.

Peripheral Synthesis (Often Forgotten)

• Uterus
• Placenta
• Amnion
• Corpus luteum
• Testis
• Heart

Physiological Actions

1. Lactation (Most Important in Humans)

• Trigger: suckling
• Reflex:
• Nipple → hypothalamus → posterior pituitary
• Action:
• Contraction of myoepithelial cells
• Result:
• Milk ejection (let-down)

👉 Milk production = prolactin, not oxytocin.

2. Parturition

• Strong role in animals.
• In humans:
• Not primary initiator
• Causes powerful uterine contractions
• Synthetic oxytocin:
• Labour induction
• Prevention/treatment of postpartum haemorrhage

Renal Effect (Exam Trap)

• High-dose IV oxytocin:
• Stimulates V2 receptors
• Causes water retention
• Can lead to iatrogenic hyponatraemia
• No natural disease due to oxytocin excess.

GnRH — FINAL EXAM CORE

Essential Rules

• Decapeptide
• Secreted into portal circulation
• Acts on gonadotrophs
• Must be pulsatile ⚠️

Pulse Logic

• Pulsatile GnRH → ↑ LH & FSH
• Continuous GnRH → receptor down-regulation → ↓ LH/FSH
• Loss of pulsatility → hypogonadotropic hypogonadism

Pulse Frequency Effects

• Fast pulses → LH dominant
• Slow pulses → FSH dominant

KNDY Neurons (Modern Exam Favourite)

• Kisspeptin → stimulates GnRH
• Neurokinin B → ↑ pulse generation
• Dynorphin → ↓ pulse frequency
• Estrogen suppresses kisspeptin (negative feedback).

Ovulation Logic

• Sustained estrogen → positive feedback
• GnRH self-priming at pituitary
• → LH surge

Clinical Locks

• Continuous GnRH agonists → medical castration
• Endometriosis
• Fibroids
• Prostate cancer
• Pulsatile GnRH → hypothalamic amenorrhoea
• Kisspeptin deficiency → delayed puberty

ONE-LINE MASTER LOCK

Posterior pituitary stores AVP and oxytocin made in hypothalamic magnocellular neurons; AVP regulates water balance via V2-mediated aquaporin insertion and supports BP via V1 vasoconstriction, while oxytocin mediates milk ejection and uterine contraction; GnRH must be pulsatile to sustain LH/FSH secretion, with frequency determining hormonal dominance.

HYPOTHALAMIC–PITUITARY CONTROL OF PUBERTY

Definition of Puberty

• Stage of physical maturation enabling sexual reproduction.
• Associated with:
• Increased growth rate
• Skeletal changes (e.g. ↑ hip width in girls)
• Increased fat and muscle
• Psychological changes

Physiology of Puberty

Central Initiation

• Puberty begins with ↑ GnRH secretion.
• GnRH neurons located in:
• Arcuate nucleus
• Other hypothalamic nuclei
• GnRH drives ↑ LH and FSH secretion.

Pre-Pubertal State

• LH and FSH secreted in very small amounts.
• Low peripheral concentrations.
• No significant gonadal stimulation.

Pubertal Transition

• ↑ Amplitude of pulsatile LH and FSH secretion.
• ↑ Mean secretion rates.
• Nocturnal rise in LH secretion becomes amplified.
• This nocturnal rhythm:
• Specific to puberty
• Disappears in adulthood

Central Programming

• Gonads not required for initiation.
• Brain is programmed to:
• Increase GnRH output
• Increase LH and FSH secretion

Peripheral Effects

• ↑ LH and FSH → gonadal maturation.
• ↑ Sex steroid secretion.
• Along with adrenal androgens, cause pubertal physical changes.

Sex-Specific Changes

Boys

• Earliest sign:
• ↑ Testicular size
• Volume > 4 ml or
• Length > 2.5 cm

Girls

• Thelarche (breast development) indicates ovarian steroid secretion.
• Estradiol secretion fluctuates widely before menarche.
• Reflects waves of follicular development without ovulation.
• Estrogen stimulates uterine growth.
• Menarche occurs when:
• Sufficient uterine growth achieved
• Estrogen withdrawal triggers first menstruation
• Primary amenorrhoea indicates underlying pathology.

Adrenarche and Gonadarche

• Axillary and pubic hair growth due to:
• Gonadal steroids (gonadarche)
• Adrenal steroids (adrenarche)

EXAM REFLEX BLOCK — Hypothalamic–Pituitary Control of Puberty 🧠🎯

Use this as your rapid-fire recall + examiner trap shield.

Core Trigger (Always start here)

• Puberty is centrally initiated by ↑ GnRH pulsatility.
• GnRH neurons: mainly arcuate nucleus (+ other hypothalamic nuclei).
• Leads to ↑ LH & FSH amplitude and mean secretion.

Pre-puberty vs Puberty (Classic Contrast)

• Pre-puberty:
• LH/FSH → very low, minimal pulses.
• Gonads inactive despite being structurally normal.
• Puberty:
• ↑ pulse amplitude, not frequency alone.
• Nocturnal LH rise appears → puberty-specific, gone in adults.

👉 Exam trap: If they ask “what changes first?” → Amplitude of pulsatile secretion.

Central Programming (High-Yield Concept)

• Gonads NOT required to start puberty.
• Brain has an intrinsic developmental clock.
• Peripheral sex steroids are effects, not triggers.

👉 Question stem with gonadal failure + pubertal LH rise = central drive intact.

Peripheral Execution

• LH/FSH → gonadal maturation.
• ↑ Sex steroids + adrenal androgens → physical pubertal changes.
• Adrenal contribution explains hair development independent of gonads.

Sex-Specific Exam Locks

Boys

• Earliest sign of puberty:
• ↑ testicular size
• Volume > 4 mL or length > 2.5 cm
• NOT voice change, NOT pubic hair.

👉 MCQ favourite: “first sign of puberty in boys?” → testicular enlargement.

Girls

• Thelarche = first clear sign → estrogen effect.
• Estradiol secretion:
• Highly fluctuating
• Follicular waves without ovulation.
• Menarche:
• Requires adequate uterine growth.
• Occurs due to estrogen withdrawal, not estrogen peak.

👉 Primary amenorrhoea = always pathological → investigate.

Adrenarche vs Gonadarche (Very Tested Pair)

• Adrenarche:
• Adrenal androgens (DHEA, DHEAS).
• Causes axillary & pubic hair.
• Gonadarche:
• Gonadal sex steroids.
• Responsible for true sexual maturation.

👉 Hair development ≠ proof of puberty onset.

One-Line Exam Reflex

Puberty is centrally programmed by increased GnRH pulsatility (↑ amplitude), producing a transient nocturnal LH rise, leading to gonadal steroid secretion; gonads execute puberty but do not initiate it.

DISORDERS OF PUBERTY, AMENORRHOEA & HYPOTHALAMO–PITUITARY DISEASE

(Logic-based, no omissions)

1. NORMAL PUBERTY → KEY CONCEPT: CONSONANCE

• Puberty follows a reliable, ordered sequence of physical and hormonal changes.
• This coordinated progression is termed consonance.
• Disorders of puberty represent early, delayed, or disordered activation of this sequence.

2. PRECOCIOUS PUBERTY

Definition

• Girls: Onset of puberty before 8 years
• Boys: Onset of puberty before 9 years

⚠️ Important epidemiological update:

• Early pubertal signs (breast development, pubic hair) are commonly seen in girls aged 6–8 years, especially Black girls.

A. CENTRAL PRECOCIOUS PUBERTY (CPP)

= Gonadotropin-dependent

Core mechanism

• Early maturation of the entire HPG axis
• Normal pubertal sequence, but too early

Features

• Full spectrum of:
• Physical pubertal changes
• Hormonal pubertal changes
• Puberty progresses normally but prematurely

Causes

• Idiopathic in:
• ~90% of girls
• Can be associated with:
• CNS tumours
• Brain injury
• Congenital brain anomalies

B. PERIPHERAL PRECOCIOUS PUBERTY (PSEUDOPUBERTY)

= Gonadotropin-independent

Core mechanism

• Excess sex steroid production
• No activation of the HPG axis

Key point

• Much less common than central precocious puberty

3. DELAYED PUBERTY

Definitions

• Boys: Testicular volume < 4 mL by age 14
• Girls: No breast development by 13–15 years

Constitutional Delay

• Most common cause
• Much more frequent in boys
• Affects growth and puberty together
• Investigations are normal by definition

Causes of Delayed Puberty (Table 16.1 – fully preserved)

A. CONSTITUTIONAL DELAY

• Common (~90%)

B. HYPOGONADOTROPHIC HYPOGONADISM (~10%)

• GnRH deficiency
• May be isolated
• Or associated with:
• Anosmia (Kallmann syndrome)
• Cognitive impairment
• Dysmorphic features (e.g. Prader–Willi syndrome)
• Gonadotrophin deficiency
• Isolated:
• Fertile eunuch syndrome (LH deficiency)
• More commonly:
• Associated with hypopituitarism

C. HYPERGONADOTROPHIC HYPOGONADISM (~10%)

• Sex chromosome abnormalities:
• Boys: Klinefelter syndrome (47,XXY)
• Girls: Turner syndrome (45,X)
• Gonadal dysgenesis with normal karyotype
• Gonadal damage:
• Viral (e.g. mumps orchitis)
• Iatrogenic (surgery, chemotherapy, radiotherapy)
• Autoimmune (often with Addison’s disease)
• Loss-of-function mutation:
• LH β-subunit
• Reduced bioactivity
• Elevated LH on immunoassay
• Gonadotrophin receptors
• Resistant ovary syndrome

4. AMENORRHOEA

Definition

• Absence of menstruation in a woman of reproductive age

Physiological amenorrhoea

• Pregnancy
• Lactation
• Childhood
• Post-menopause

Types

Primary amenorrhoea

• No menarche by 16 years
• Can be a feature of delayed puberty

Secondary amenorrhoea

• Absence of menstruation for ≥3 months
• In a previously menstruating woman

CRITICAL CLINICAL LOGIC: BREASTS + UTERUS

Endocrine classification

• High LH/FSH → Primary ovarian failure
• Low LH/FSH → Hypothalamo–pituitary dysfunction

5. DISEASES OF THE HYPOTHALAMUS & PITUITARY

General principles

• Disease manifests as:
• Hormone deficiency
• Hormone excess
• Hormone excess:
• Usually due to pituitary adenoma
• Typically single-hormone over-secretion
• Pituitary tumours:
• Mostly benign adenomas
• May compress optic chiasm
• Carcinomas are rare, aggressive, invasive

Axis terminology

• Primary disorder: End-organ disease
• Secondary disorder: Pituitary dysfunction
• Tertiary disorder: Hypothalamic dysfunction

🧠 EXAM REFLEX BLOCK — Disorders of Puberty, Amenorrhoea & HPO Axis

Use this as instant recall logic in SBAs, vivas, and structured essays.

1️⃣ PUBERTY — FIRST REFLEX

Ask: Is the sequence normal but mistimed, or disordered?

• Normal order, early → Central precocious puberty
• Isolated / mismatched features → Peripheral precocious puberty
• Slow child + late puberty → Constitutional delay

👉 Keyword: Consonance = ordered, coordinated pubertal progression.

2️⃣ PRECOCIOUS PUBERTY — CORE SPLIT

Age cut-offs

• Girls < 8 yrs
• Boys < 9 yrs

Central (GnRH-dependent)

• Entire HPG axis switched on early
• Normal pubertal sequence
• Idiopathic in ~90% of girls
• Think CNS causes if boy or neurological signs

Peripheral (GnRH-independent)

• Sex steroids ↑ without HPG activation
• Puberty not consonant
• Much less common

3️⃣ DELAYED PUBERTY — FIRST DIAGNOSIS IS…

➡️ Constitutional delay (especially boys)

Definitions

• Boys: testes < 4 mL at 14 yrs
• Girls: no breast development by 13–15 yrs

Three-way split

• Constitutional delay (~90%)
• Hypogonadotrophic hypogonadism (central problem)
• Hypergonadotrophic hypogonadism (gonadal failure)

4️⃣ DELAYED PUBERTY — EXAM PATTERNS

Low LH/FSH (Hypogonadotrophic hypogonadism (central problem))

• GnRH deficiency
• Kallmann = delayed puberty + anosmia
• Often part of hypopituitarism

High LH/FSH (Hypergonadotrophic hypogonadism (gonadal failure))

• Gonadal failure/dysgenesis
• Turner (girls), Klinefelter (boys)
• Gonadal damage (mumps, chemo, auto-immune)
• Receptor defects → hormones high but ineffective

5️⃣ AMENORRHOEA — ALWAYS START HERE

Physiology first

• Pregnancy, lactation, childhood, menopause

Definitions

• Primary: no menarche by 16 yrs
• Secondary: no periods ≥3 months

6️⃣ AMENORRHOEA — GOLD TABLE REFLEX

Breasts + Uterus = localisation

• ❌ Breasts + ✅ Uterus → Axis failure before puberty
• ✅ Breasts + ✅ Uterus → Axis failure after puberty
• ✅ Breasts + ❌ Uterus → Androgen insensitivity / Müllerian agenesis

This table alone answers multiple MCQs.

7️⃣ AMENORRHOEA — HORMONAL LOGIC

• High LH/FSH → Ovarian failure
• Low LH/FSH → Hypothalamo-pituitary cause

Never miss this step.

8️⃣ HYPOTHALAMO–PITUITARY DISEASE — EXAM RULES

• Think deficiency OR excess
• Excess = usually single hormone adenoma
• Most tumours = benign
• Visual field loss = optic chiasm compression
• Carcinoma = rare, aggressive

9️⃣ AXIS TERMINOLOGY — MUST-USE WORDS

• Primary → end-organ problem
• Secondary → pituitary problem
• Tertiary → hypothalamic problem

Examiners expect this language.

🔒 FINAL MEMORY LOCK

If confused in exam:

1. Age
2. Sequence (consonant or not)
3. Breasts + uterus
4. LH/FSH direction
5. Primary vs secondary vs tertiary

6. ACROMEGALY

Definition

• Chronic exposure to excess GH

Epidemiology

• Incidence: ~3/million/year
• Onset: 3rd–4th decade
• Equal in both sexes
• Delay to diagnosis: 5–10 years

Causes

• 95%: GH-secreting pituitary adenomas
• Often macroadenomas (>1 cm)
• 15%: Co-secrete PRL
• Rare causes:
• Hypothalamic tumours (glioma, hamartoma)
• Peripheral tumours (pancreatic adenocarcinoma)

Pathophysiology

• GH secretion:
• Still pulsatile
• Increased amplitude, duration, frequency
• Absent nocturnal surge
• Abnormal suppression & stimulation responses
• Effects mediated mainly by IGF-I
• Bone, cartilage, soft tissue proliferation
• Organ enlargement

Pregnancy physiology

• Placenta produces:
• Variant GH
• GH-releasing hormone
• IGF-I
• Placental GH:
• Rises through pregnancy
• Falls rapidly after delivery

Clinical features (Table 16.2 – preserved)

Skeletal

• Arthralgia/arthritis (85%)
• Carpal tunnel (50%)
• Enlarged hands/feet (100%)
• Jaw protrusion (90%)
• Dental malocclusion (80%)
• Osteoarthritis (30%)

Skin

• Excessive sweating (85%)
• Greasy skin, skin tags (60%)

Cardiovascular

• Angina (5–10%)
• Hypertension (50%)
• Cardiomyopathy (5%)

Respiratory

• Daytime somnolence (30%)
• Obstructive sleep apnoea (30%)

Metabolic

• Polydipsia/polyuria (5%)
• Neuropathy (50%)
• Retinopathy (15%)

Renal

• Renal colic (20%)
• Renal stones (20%)

Endocrine

• Menstrual irregularity (50%)
• Impotence (40%)
• Hypogonadism (40%)

Mortality

• Cardiovascular/cerebrovascular: 36–62%
• Respiratory: 0–25%
• Malignancy: 9–25%
• Higher if diabetes or hypertension present

Diagnosis

• Oral glucose tolerance test
• 75 g glucose
• Normal: GH < 2 mU/L
• Acromegaly:
• Failure to suppress
• May show paradoxical increase
• TRH or GnRH stimulation:
• GH rises in 70–80%
• Visual field testing:
• Bitemporal hemianopia
• Imaging:
• MRI – modality of choice

Treatment

• Surgery (best if tumour <10 mm)
• Medical therapy
• Radiotherapy
• Panhypopituitarism in 15–20% after years

🧠 EXAM RECALL BLOCK — ACROMEGALY

Definition

• Chronic exposure to excess growth hormone (GH).

Epidemiology

• Incidence ~3/million/year.
• Onset 3rd–4th decade.
• Equal sex distribution.
• Diagnosis delayed 5–10 years.

Cause

• ~95%: GH-secreting pituitary adenoma.
• Usually macroadenoma (>1 cm).
• ~15% co-secrete prolactin.
• Rare: hypothalamic tumours, ectopic GH/GHRH (e.g. pancreatic).

Pathophysiology

• GH secretion remains pulsatile.
• ↑ Amplitude, duration, frequency.
• Absent nocturnal surge.
• Failure of suppression with glucose.
• Effects mediated mainly by IGF-I → bone, cartilage, soft-tissue, organ overgrowth.

Pregnancy physiology

• Placenta produces variant GH, GHRH, IGF-I.
• Placental GH rises during pregnancy, falls rapidly post-delivery.

Clinical features

• Skeletal: enlarged hands/feet (100%), prognathism (90%), malocclusion (80%), arthralgia (85%), carpal tunnel (50%).
• Skin: sweating (85%), greasy skin/skin tags (60%).
• CVS: hypertension (50%), cardiomyopathy (5%), angina (5–10%).
• Respiratory: OSA + daytime somnolence (~30%).
• Metabolic/neurologic: neuropathy (50%), PU/PD (5%), retinopathy (15%).
• Renal: renal colic/stones (20%).
• Endocrine: menstrual irregularity (50%), impotence (40%), hypogonadism (40%).

Mortality

• Cardio/cerebrovascular: 36–62% (commonest).
• Respiratory: 0–25%.
• Malignancy: 9–25%.
• Risk ↑ with diabetes or hypertension.

Diagnosis

• OGTT (75 g glucose):
• Normal: GH < 2 mU/L.
• Acromegaly: fails to suppress Gh ± paradoxical rise.
• TRH or GnRH stimulation: GH rises in 70–80%.
• Visual fields: bitemporal hemianopia.
• MRI pituitary: investigation of choice.

Treatment

• Transsphenoidal surgery (best if tumour <10 mm).
• Medical therapy (somatostatin analogues, dopamine agonists, GH receptor antagonists).
• Radiotherapy → panhypopituitarism 15–20% (late).

7. GROWTH HORMONE DEFICIENCY

Childhood

• Detected early due to reduced growth velocity

Adults

• Due to hypothalamo–pituitary damage

Diagnosis

• Insulin tolerance test
• Peak GH < 9 mU/L
• Contraindications:
• Seizures
• Ischaemic heart disease

8. HYPERPROLACTINAEMIA

Causes (Table 16.3 – preserved)

Common (~90%)

• Drugs:
• Neuroleptics (phenothiazines)
• Dopamine antagonists (metoclopramide)
• Primary hypothyroidism

Uncommon (~10%)

• Macroprolactinaemia
• Stalk syndrome
• Dopamine interruption
• PRL <3000 mU/L
• Pituitary tumours
• PRL >5000 mU/L

Rare (<1%)

• Renal failure

9. PROLACTINOMA

Most common hormone-secreting pituitary tumour

Classification

• Microprolactinoma: <10 mm
• Macroprolactinoma: >10 mm

Physiology of lactotrophs

• Normally:
• ~20% of pituitary cells
• Pregnancy:
• Up to 50%
• Postpartum:
• Partial regression
• Hyperplasia persists up to 11 months
• Decidual PRL:
• Same as pituitary PRL
• Not inhibited by dopamine

Clinical differences

• Women:
• Smaller tumours
• Galactorrhoea
• Amenorrhoea
• Men:
• Larger tumours
• Subtle hypogonadism

Management

• First-line: Dopamine agonists
• Cabergoline
• Bromocriptine
• Safe in pregnancy
• Surgery / radiotherapy / temozolomide if resistant

Pregnancy risk of enlargement

• Microprolactinoma: 1.3%
• Untreated macroprolactinoma: 23.2%
• Treated macroprolactinoma: 2.8%

10. NON-FUNCTIONING PITUITARY ADENOMAS

• No hormone excess
• Symptoms due to mass effect:
• Headache
• Visual defects
• Cranial nerve palsies
• Hypopituitarism
• Investigations:
• Pituitary function
• Visual fields
• MRI
• Treatment:
• Surgery ± radiotherapy

11. CRANIOPHARYNGIOMA & RATHKE CLEFT CYST

Craniopharyngioma

• Extra-axial
• Squamous epithelial
• Calcified
• Benign histology, malignant behaviour
• Age: usually <20 years
• Symptoms:
• Raised ICP
• Hypopituitarism + DI
• Visual field defects
• Treatment:
• Surgery + radiotherapy
• Hormone replacement

Rathke cleft cyst

• Benign, epithelium-lined
• Intrasellar
• Surgery only if symptomatic
• Approach: trans-sphenoidal

12. DIABETES INSIPIDUS

Central DI

• ↓ AVP secretion
• Causes:
• Hypothalamic osmoreceptors
• Supraoptic/paraventricular nuclei
• Pituitary stalk
• Posterior pituitary lesions rarely permanent

Nephrogenic DI

• Renal resistance to AVP
• Causes:
• CKD
• Lithium
• Hypercalcaemia
• Hypokalaemia
• Tubulointerstitial disease
• Genetic:
• X-linked V2 receptor defect
• Autosomal recessive aquaporin-2 mutation

Treatment

• Desmopressin
• Avoid hyponatraemia

13. LYMPHOCYTIC HYPOPHYSITIS

Nature

• Autoimmune inflammatory disorder
• Pituitary ± stalk

Epidemiology

• Common in:
• Pregnancy
• Postpartum
• Can affect any age/sex
• Associated with autoimmune disease

Presentation

• Mimics pituitary adenoma:
• Headache
• Visual loss (bitemporal hemianopia)
• Hypopituitarism
• Diabetes insipidus
• Diplopia, orbital pain (cavernous sinus)

Classification

• Primary (idiopathic)
• Secondary:
• Sarcoidosis
• TB
• Langerhans cell disease
• Wegener’s
• IgG4-related disease

Treatment

• First-line: High-dose corticosteroids
• Hormone replacement often required
• 72% need lifelong replacement
• Surgery:
• Visual loss
• Failed medical therapy
• Radiotherapy:
• In refractory cases

🧠 EXAM RECALL BLOCK — PITUITARY DISORDERS (7–13)

(Ultra-fast • zero explanation • examiner-triggered recall)

7. GROWTH HORMONE DEFICIENCY

Childhood

• Early detection due to ↓ growth velocity.

Adults

• Due to hypothalamo–pituitary damage.

Diagnosis

• Insulin tolerance test (gold standard).
• Peak GH < 9 mU/L.

Contraindications for insulin tolerance test(must-remember)

• Seizure disorder
• Ischaemic heart disease

8. HYPERPROLACTINAEMIA

Common causes (~90%)

• Drugs:
• Neuroleptics (phenothiazines)
• Dopamine antagonists (metoclopramide)
• Primary hypothyroidism

Uncommon (~10%)

• Macroprolactinaemia
• Stalk syndrome
• Dopamine interruption
• moderately high prolactin
• PRL < 3000 mU/L
• Pituitary tumours
• PRL > 5000 mU/L

Rare (<1%)

• Chronic renal failure

9. PROLACTINOMA

Key fact

• Most common hormone-secreting pituitary tumour.

Size

• Microprolactinoma: < 10 mm
• Macroprolactinoma: > 10 mm

Lactotroph physiology

• Normal: ~20% of pituitary cells
• Pregnancy: ↑ to ~50%
• Postpartum: partial regression, hyperplasia up to 11 months
• Decidual prolactin:
• Same as pituitary PRL
• Not dopamine-inhibited

Sex differences

• Women: smaller tumours, galactorrhoea, amenorrhoea
• Men: larger tumours, subtle hypogonadism

Management

• First-line: dopamine agonists
• Cabergoline
• Bromocriptine
• Safe in pregnancy
• Resistant cases → surgery / radiotherapy / temozolomide

Pregnancy risk of enlargement

• Microprolactinoma: 1.3%
• Untreated macroprolactinoma: 23.2%
• Treated macroprolactinoma: 2.8%

10. NON-FUNCTIONING PITUITARY ADENOMAS

Hormones

• No hormone excess

Symptoms = mass effect

• Headache
• Visual defects
• Cranial nerve palsies
• Hypopituitarism

Investigations

• Pituitary function tests
• Visual fields
• MRI

Treatment

• Surgery ± radiotherapy

11. CRANIOPHARYNGIOMA & RATHKE CLEFT CYST

Craniopharyngioma

• Extra-axial
• Squamous epithelial
• Calcified
• Benign histology, malignant behaviour
• Age: usually < 20 years

Presentation

• Raised ICP
• Hypopituitarism + DI
• Visual field defects

Treatment

• Surgery + radiotherapy
• Hormone replacement

Rathke cleft cyst

• Benign, epithelium-lined
• Intrasellar
• Surgery only if symptomatic
• Trans-sphenoidal approach

12. DIABETES INSIPIDUS

Central DI

• ↓ AVP secretion
• Causes:
• Hypothalamic osmoreceptors
• Supraoptic / paraventricular nuclei
• Pituitary stalk
• Posterior pituitary lesions rarely permanent

Nephrogenic DI

• Renal resistance to AVP
• Causes:
• CKD
• Lithium
• Hypercalcaemia
• Hypokalaemia
• Tubulointerstitial disease
• Genetic:
• X-linked V2 receptor defect
• AR aquaporin-2 mutation

Treatment

• Desmopressin
• Avoid hyponatraemia

13. LYMPHOCYTIC HYPOPHYSITIS

Nature

• Autoimmune inflammatory disorder
• Pituitary ± stalk

Epidemiology

• Common in pregnancy & postpartum
• Any age/sex
• Associated with autoimmune disease

Presentation (adenoma mimic)

• Headache
• Bitemporal hemianopia
• Hypopituitarism
• Diabetes insipidus
• Diplopia, orbital pain (cavernous sinus)

Classification

• Primary (idiopathic)
• Secondary:
• Sarcoidosis
• TB
• Langerhans cell disease
• Wegener’s
• IgG4-related disease

Treatment

• First-line: high-dose corticosteroids
• Hormone replacement common
• 72% need lifelong replacement
• Surgery: visual loss / failed medical therapy
• Radiotherapy: refractory cases

Pituitary diseases in pregnancy + Sheehan + Premature ovarian failure

(Logic-based note, zero omission)

1) Prolactinoma in pregnancy

A. Core endocrine logic (why symptoms happen)

• Excess PRL directly inhibits pulsatile GnRH secretion.
• This causes anovulation/amenorrhoea → infertility.
• Dopamine agonists correct hyperprolactinaemia and restore ovulation in ~90% of women with prolactinoma.

B. Two key pregnancy issues (the exam framework)

Issue 1 — Dopamine agonist exposure in early pregnancy

• Concern: fetal exposure before pregnancy is discovered.
• Principle: limit fetal exposure to dopamine agonists.
• Bromocriptine: seems safe in pregnancy.
• Cabergoline: available data suggest safe, but evidence is from a small number of pregnancies.
• Pergolide + quinagolide: safety data too limited to recommend use in pregnancy.
• Reported heart valve damage with high-dose cabergoline:
• Not demonstrated with cabergoline at hyperprolactinaemia treatment doses.
• Not demonstrated with bromocriptine.
• Not demonstrated with quinagolide (noted as a non-ergot dopamine agonist).

Issue 2 — Effect of pregnancy on the prolactinoma

• Pregnancy stimulates normal lactotrophs → normal pituitary enlargement.
• This does not necessarily mean the adenoma enlarges.
• Prolactinomas becoming symptomatic in pregnancy are uncommon.
• Symptoms suggesting tumour growth:
• Headache
• Visual field changes
• Risk of clinically significant enlargement:
• Microprolactinoma: 1–2%
• Untreated macroprolactinoma: about 20%
• Previously treated macroprolactinoma (surgery/radiation/both): 2–5%
• If a prolactinoma has shrunk on dopamine agonist, then after stopping treatment, there is a reduced chance of symptomatic growth during pregnancy.

C. What to do if symptomatic during pregnancy (management logic)

• If a pregnant woman with prolactinoma becomes symptomatic:
• Restart medical treatment is recommended.
• Symptoms usually regress quickly.
• If not responding to medical treatment OR if visual deterioration continues:
• Transsphenoidal surgery or delivery is an alternative.
• Monitoring in known macroadenoma pregnancy:
• Monthly visual field examinations are important.
• MRI is performed if symptoms of enlargement and/or visual field defects develop.

D. Postpartum / lactation facts (must-know)

• Breastfeeding has not been associated with growth of an underlying prolactinoma.
• After pregnancy:
• Resolution of hyperprolactinaemia and regression of prolactinoma have been reported.
• Idiopathic hyperprolactinaemia is even more likely to resolve after pregnancy.

2) Sheehan syndrome (postpartum pituitary necrosis)

A. Trigger + definition

• Severe haemorrhage, shock, or hypotension during or before parturition can cause postpartum pituitary necrosis (Sheehan syndrome).
• Leads to partial or complete hypopituitarism.
• Now uncommon due to improved obstetric practice.

B. Pathogenesis (stepwise mechanism)

• Pregnancy causes ~50% increase in pituitary volume.
• Sudden BP fall (e.g., postpartum haemorrhage) → hypoperfusion → infarction → ischaemia → cellular damage + oedema.
• Oedema → pituitary swelling.
• More likely when there is a known or unknown pituitary mass.
• Higher risk group noted:
• Type 1 diabetes in pregnancy, especially with pre-existing vascular disease.

C. Which parts are affected (vascular logic)

• Usually anterior pituitary is affected.
• Posterior pituitary + hypothalamus are less vulnerable because they are supplied by:
• Inferior hypophyseal artery
• Circle of Willis
• Some women have impaired AVP secretion → partial or overt diabetes insipidus.

D. Clinical presentation (depends on % destruction)

• Presentation is highly variable.

Severe destruction (95–99% anterior pituitary destroyed)

• Postpartum failure of lactation
• Secondary amenorrhoea
• Loss of axillary and pubic hair
• Genital and breast atrophy
• Increasing signs of:
• Secondary hypothyroidism
• Adrenocortical insufficiency

Less extensive destruction (50–95%)

• Atypical form with loss of one or more hormones.
• Pattern of trophic hormone loss is unpredictable, but invariably results in:
• Hypothyroidism (impaired TSH secretion)
• Hypoadrenalism (impaired ACTH secretion)

Neuropsychiatric + diabetes clue

• Mental disturbances are frequent, sometimes overt psychosis.
• These revert with hormone replacement.
• Women with type 1 diabetes may present with decreasing insulin requirements.

E. Imaging

• MRI or CT is indicated to exclude mass lesions.
• Long-standing Sheehan:
• Sella often empty, filled with CSF.
• Sometimes small remnants of pituitary tissue seen.

F. Treatment + prognosis facts

• Treatment is hormone replacement.
• Sometimes gonadotrophin secretion is preserved → pregnancy is possible.
• Spontaneous recovery from hypopituitarism after postpartum haemorrhage has been reported.

3) Premature ovarian failure (POF)

A. Definitions (get the exam wording right)

• Menopause: defined by the last menstrual period, ends reproductive phase.
• Average menopause age: ~51 years.
• Ovarian failure diagnosis: sex steroid deficiency + elevated gonadotrophins + amenorrhoea.
• Premature ovarian failure (POF):
• Statistically: ovarian failure occurring >2 SD below mean menopause age for reference population.
• Or arbitrarily: before age 40 years.

B. Epidemiology + who it affects

• Can occur before or after menarche.
• Prevalence:
• 1% of women under 40
• 0.1% under 30
• Varies by ethnicity:
• Lower risk in women of oriental origin
• Higher risk in black women than white women
• Frequency in amenorrhoea workups:
• 10–28% of primary amenorrhoea
• 4–18% of secondary amenorrhoea

C. Pathophysiology (what goes wrong)

• POF results from either:
• Follicle dysfunction
• Follicle depletion
• Key contrast with normal menopause:
• ~50% of women with POF have intermittent ovarian function up to 15 years after onset.
• Pregnancy can occur even:
• After a diagnosis of POF
• Even if no follicles are seen on ovarian biopsy

D. Causes (full list preserved)

• In most women: no identifiable aetiology.
• Proposed spontaneous mechanisms:
• Small initial follicle pool
• Inappropriate luteinisation of Graafian follicles
• Other causes:
• Chromosomal/genetic abnormalities (X chromosome or autosomes)
• Autoimmune ovarian damage with positive anti-ovarian antibodies
• Iatrogenic: pelvic surgery, radiotherapy, chemotherapy
• Environmental: viral infections or toxins (no clear mechanism)

E. Clinical presentation (variable patterns)

• Rare presentation:
• Primary amenorrhoea with variable secondary sexual development
• More common:
• Secondary amenorrhoea
• Presentation contexts:
• Symptoms of estrogen deficiency or menstrual disturbance
• Infertility work-up
• Part of genetic/autoimmune syndrome
• Chromosomal defects:
• Often primary amenorrhoea + absent secondary sex characteristics
• Mosaicism:
• Some functioning gonadal tissue
• Variable sexual development + transient menstruation possible
• No specific warning signs of approaching POF.
• “Prodromal POF”:
• ~50% have oligomenorrhoea or dysfunctional uterine bleeding before POF develops
• Acute onset in 25%:
• After pregnancy/delivery
• Or after stopping oral contraceptive pill
• Vasomotor symptoms:
• Only in women with secondary amenorrhoea
• May start even when periods still regular → suggests prodromal POF
• Fertility pattern:
• Usually normal before disorder starts
• Decline may show as resistant ovaries or rising FSH

F. Health risks (long-term consequences)

• Women with POF have nearly twice the age-specific mortality risk.
• Because sex steroid deficiency starts earlier and lasts longer:
• Higher risk of osteoporosis
• Especially high if POF occurs before peak adult bone mass
• Bone density statistic:
• Two-thirds of women with normal karyotype + POF have BMD 1 SD below age-matched mean despite standard hormonal therapy
• Translates to 2.6-fold increased hip fracture risk
• Cardiovascular risk increased:
• Increased mortality documented for:
• Coronary heart disease (OR death 1.29)
• Stroke (OR death 3.07)
• Cancer (OR death 1.83)
• Other causes (OR death 2.14)

4) Autoimmune POF (subset, high-yield)

A. How common + what form is reversible

• Autoimmune mechanisms involved in up to 30% of POF.
• Autoimmune oophoritis:
• Important cause in 10–30%
• Cause of reversible POF
• Can be humoral or cellular

B. Antibodies described (specific list)

• Against steroidogenic enzymes (e.g., 3-hydroxy steroid dehydrogenase)
• Against gonadotrophins and their receptors
• Against corpus luteum
• Against zona pellucida
• Against oocyte
• Specificity for disease is unknown.

C. Lymphocytic oophoritis associations

• Increased peripheral T-lymphocyte activity
• Can be isolated or associated with:
• Addison disease
• Diabetes mellitus
• Myasthenia gravis
• Systemic lupus erythematosus
• Rheumatoid arthritis
• Autoimmune hypothyroidism
• Lymphocytic infiltration may be present in ovarian hilum with lymphocytes accumulating around neural tissue.

D. Autoantibody prevalence facts

• 40% of women with POF have at least one organ-specific autoantibody.
• Most common: antithyroid antibodies (~20%).

5) Genetics, infections, and iatrogenic causes (expanded facts preserved)

Familial risk

• 5–30% have another affected female relative.
• Inheritance could be:
• X-linked
• Autosomal dominant
• Autosomal recessive
• Causal mutation often unknown.

Chromosomal/genetic associations

• Turner syndrome (45,X)
• Triple X syndrome
• Fragile X syndrome
• Fragile X premutation
• Swyer syndrome (pure gonadal dysgenesis with XY constitution)
• Blepharophimosis
• Perrault syndrome
• Down syndrome

Infections linked

• Oophoritis after:
• Mumps
• Malaria
• Varicella
• Shigella infections

Radiotherapy / chemotherapy (dose facts)

• Younger women more resistant; prepubertal ovaries least susceptible.
• Complete ovarian failure:
• 20 Gy in women under 40
• 6 Gy in older women

6) Diagnosis of POF (exam criteria)

Core diagnostic rule

• Elevated serum FSH 40 IU/L
• On at least two occasions
• Separated by a few weeks

Why two samples are required

• Natural history is variable with relapse/remission (“fluctuating ovarian function”).

Pregnancy rate despite diagnosis

• Approximately 1–5% pregnancy rate reported.

Tests that add little / what imaging is for

• Ovarian biopsy:
• Adds little
• Small sample not predictive of natural history
• Pelvic ultrasound:
• Not predictive
• May help identify candidates for oocyte preservation

Additional assessments

• Autoimmune screen:
• Thyroid and adrenal autoantibodies for future surveillance
• Family history:
• Can identify other affected members in up to 30%

Genetic screening facts

• Increasingly used in:
• Familial POF
• Sporadic POF with high suspicion
• Fragile X premutation:
• 15% in women with POF + positive family history
• 3% in sporadic presentations
• Karyotype + fragile X premutation screening should be considered with:
• Family history
• Unusually young onset

7) Management of POF (3 components, preserved)

• Medical treatment
• Fertility advice
• Psychological support

Core medical focus

• Quality of life + bone protection → hormone replacement therapy

Fertility options mentioned

• Oocyte donation
• Adoption

Psychological care

• Personal and emotional support for impact on health and relationships

Follow-up

• Long-term follow-up to:
• Monitor hormone replacement therapy
• Surveillance for emerging autoimmune pathology

🔒 EXAM-REFLEX BLOCK

(Pituitary disease in pregnancy · Sheehan syndrome · Premature ovarian failure)

1️⃣ Prolactinoma in pregnancy — reflex logic

Core reflex

• High PRL → GnRH suppression → anovulation → infertility
• Dopamine agonists restore ovulation (~90%)

Pregnancy risks — remember 2 questions only

1. Drug exposure early pregnancy
• Bromocriptine → SAFER
• Cabergoline → probably safe (limited data)
• Pergolide / Quinagolide → avoid
• Valve disease → only high-dose cabergoline (not hyperprolactinaemia doses)
2. Tumour growth risk
• Microprolactinoma → 1–2%
• Untreated macro → ~20%
• Treated macro → 2–5%

Symptoms = growth

• Headache
• Visual field defects

Management reflex

• Symptomatic → restart dopamine agonist
• If fails / vision worsening → transsphenoidal surgery OR delivery
• Macroadenoma → monthly visual fields
• MRI → only if symptoms

Post-partum reflex

• Breastfeeding does NOT enlarge prolactinoma
• PRL levels may normalize after pregnancy
• Idiopathic hyperprolactinaemia often resolves

2️⃣ Sheehan syndrome — never miss this

Trigger

• Postpartum haemorrhage / shock / hypotension

Pathogenesis chain (must recall in order)

• Pregnancy → 50% pituitary enlargement wenawa
• ↓ BP → hypoperfusion → infarction → oedema → necrosis

Which part dies?

• Anterior pituitary mainly
• Posterior spared (inferior hypophyseal artery + Circle of Willis)
• DI possible → partial AVP deficiency

Clinical reflex patterns

Severe (95–99% loss):

• Failure of lactation
• Amenorrhoea
• Loss of pubic/axillary hair
• Hypothyroidism + adrenal insufficiency

Partial (50–95%):

• Hormone loss unpredictable
• ALWAYS → ACTH + TSH deficiency

Key exam clues

• Psychosis / mental changes
• Falling insulin needs in type 1 diabetes

Imaging reflex

• Chronic → empty sella (CSF-filled)
• MRI/CT → exclude mass

Treatment pearl

• Hormone replacement
• Gonadotrophins may be preserved → pregnancy possible
• Rare spontaneous recovery exists

3️⃣ Premature ovarian failure (POF) — definition trap area

Definition reflex

• Ovarian failure before 40
• Low estrogen + high FSH + amenorrhoea
• Menopause mean = 51 yrs

Epidemiology numbers (must remember)

• <40 yrs → 1%
• <30 yrs → 0.1%
• Primary amenorrhoea → 10–28%
• Secondary amenorrhoea → 4–18%

Pathophysiology contrast

• Follicle depletion OR dysfunction
• 50% intermittent ovarian activity
• Pregnancy possible even with empty biopsy

4️⃣ Autoimmune POF — reversible subset

Key numbers

• Autoimmune mechanism → up to 30%
• Oophoritis → 10–30%, reversible

Antibodies (recognition list)

• Steroidogenic enzymes
• Gonadotrophins / receptors
• Corpus luteum
• Zona pellucida
• Oocyte

Associations (always test)

• Addison disease
• Type 1 diabetes
• Myasthenia gravis
• SLE
• RA
• Autoimmune hypothyroidism

Autoantibody prevalence

• Any organ-specific antibody → 40%
• Antithyroid → ~20%

5️⃣ Genetics / iatrogenic — exam favourites

Genetic associations

• Turner (45,X)
• Triple X
• Fragile X (premutation)
• Swyer syndrome (XY)
• Perrault
• Blepharophimosis
• Down syndrome

Familial risk

• 5–30%
• X-linked / AD / AR possible

Radiation thresholds

• <40 yrs → 20 Gy
• Older women → 6 Gy
• Prepubertal ovaries → most resistant

6️⃣ Diagnosis of POF — non-negotiable rule

• FSH ≥40 IU/L
• Two samples
• Few weeks apart

Why? → Fluctuating ovarian function

Tests that DON’T help

• Ovarian biopsy → poor predictor
• Pelvic US → not predictive (useful for fertility planning only)

Genetic screening triggers

• Family history
• Very early onset
• Fragile X premutation:
• 15% familial
• 3% sporadic

7️⃣ Management of POF — 3-pillar reflex

1. Hormone replacement → QoL + bone protection
2. Fertility counselling → oocyte donation / adoption
3. Psychological support

Long-term risks (numbers examiners like)

• Mortality × 2
• Hip fracture risk × 2.6
• CHD death OR 1.29
• Stroke death OR 3.07

🧠 FINAL EXAM LOCK

If the question says pregnancy + pituitary → think prolactinoma vs Sheehan.

If it says amenorrhoea + high FSH <40 yrs → POF until proven otherwise.

If it says PPH + no lactation → Sheehan, don’t miss it.